Please ensure Javascript is enabled for purposes of website accessibility

Rite Aid Loosens Its Criteria for Free COVID-19 Testing

By Cory Renauer – Apr 28, 2020 at 2:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Adults with any of a now-expanded list of coronavirus symptoms can get a self-swab test at 25 stores in eight states.

Rite Aid (RAD -5.16%) on Tuesday announced it would make free COVID-19 testing available to a larger group than before. Adults exhibiting any of the following symptoms -- fever, cough, shortness of breath, chills, repeated shaking with chills, muscle pain, headache, sore throat, and new loss of taste or smell -- are eligible for diagnostic screening at one of its 25 self-swab drive-up test sites at no cost. Each site has the capacity to handle around 400 tests daily. 

Pharmacists on-site will watch patients self-swab their nasal cavities before sending the samples off to be tested by Opko Health (OPK -4.85%) subsidiary, BioReference Laboratories.

Lots of sample tubes and a pipette.

Image source: Getty Images.

Opko isn't the only partner teaming up with Rite Aid to facilitate these coronavirus tests. Verily, an Alphabet (GOOG -0.31%) (GOOGL -0.33%) subsidiary, is working with Rite Aid to screen patients, schedule their tests, and return the results.

Automated prescreening

Rite Aid is making use of Verily's Baseline COVID-19 Program, which was initially established in California to securely manage health information in a way that makes it easier for people to participate in clinical research. The program should also make it easier to follow up with people as screening criteria change.

Ideally, everyone would be able to receive COVID-19 tests regularly so that public health officials could monitor the disease's spread and intervene quickly before new breakouts get out of control. Testing capacity is growing, but it isn't anywhere near where it needs to be for the U.S. to have the ability to test everyone who should be tested.

As test availability and processing capacity increase -- and as the Centers for Disease Control updates its COVID-19 testing guidelines -- people who previously were deemed ineligible can become eligible. Those who are initially rejected at Rite Aid by Verily's system will, in theory, receive a notification as soon as they do become eligible. 

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Cory Renauer owns shares of Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rite Aid Stock Quote
Rite Aid
$5.42 (-5.16%) $0.29
Alphabet (A shares) Stock Quote
Alphabet (A shares)
$101.30 (-0.33%) $0.34
Opko Health Stock Quote
Opko Health
$1.91 (-4.85%) $0.10
Alphabet (C shares) Stock Quote
Alphabet (C shares)
$102.09 (-0.31%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.